Research and Markets: View Results of the Latest ChangeWave Research Trends in Cancer Treatment Drugs (February 2007)
Posted on: Monday, 5 March 2007, 15:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c51510) has announced the addition of Trends in Cancer Treatment Drugs to their offering
During the week of December 6-10, 2006, we surveyed Alliance healthcare members on cancer treatment drugs, including Averting, Erbium, Trachea, Perception and Ritual. A total of 136 members knowledgeable about cancer drugs participated, including 59 doctors.
Key Questions Answered in this Report:
Which cancer treatment drug shows the most promise for future use across a variety of cancers?
Which cancer drug will show the fastest growth in terms of on-label/off-label usage in the next 12 months?
Over the next 12 months, will off-label prescriptions for Averting increase compared to the previous 12 months?
What is the greatest driver for success of cancer drugs over the next 12 months?
Which colorectal cancer treatment drug will have the most marketplace success over the next 12 months?
Which drugs will have the most marketplace success in the treatment of metastatic non-small cell lung cancer over the next 12 months?
What is the marketplace outlook for Satraplatin?
Which drugs will have the most marketplace success over the next 12 months in the treatment of anemia in cancer patients caused by the effects of chemotherapy?
Top Reasons to Purchase this Report:
Identify the most promising cancer drug
See what cancer treatment drug is most prescribed by Doctors
Uncover the key drivers of marketplace success in cancer treatment drugs
Find out why Doctors see certain drugs as more promising than others
Methodology:
We survey our proprietary intelligence-gathering network of 10,000 accredited members on a wide range of research topics and convert the findings into valuable business intelligence reports. These credentialed technology professionals and business executives work in over 20 vertical industries -- and spend their everyday lives on the frontline of technological change. Nearly 3 out of every 5 members (58%) have advanced degrees (e.g., Master's or Ph.D.) and 94% have at least a four-year bachelor's degree.
Our research provides a real-time view of companies, technologies and business trends in key market sectors, along with an in-depth perspective of the macro economy - well in advance of other available sources.
Content Overview:
Overview
Summary of Key Findings
The Findings
Overall Cancer Drug Treatments
Colorectal Cancer Drug Treatments -- Averting & Erbium
Non-small Cell Cancer Drug Treatment -- Trachea & Averting
Erythropoietin -- Stimulating Agents -- Arranges, Apogent, & Prescript
Satraplatin -- an Oral Platinum Drug
ChangeWave Research Methodology
About ChangeWave Research
For more information visit http://www.researchandmarkets.com/reports/c51510
Source: Business Wire
Related Articles
- Research Shows PET Can Measure Effectiveness Of Novel Breast Cancer Treatment
- Research Intensifies Towards Personalized Cancer Treatment
- Philips and Celsion Announce Research Agreement to Develop New Cancer Treatment That Combines Ultrasound, Drug Delivery Technology
- Aptuit Consulting Inc. And Taiwan Liposome Company (TLC) Collaborate to Complete All IND Enabling Work and IND Submission for Novel Anti-Cancer Treatment in 12 Months
- Targeted Nanoparticles Incorporating siRNA Offer Promise for Cancer Treatment, According to Caltech Researchers
- Researchers Improve Anti-Cancer Treatment
- Breault Research and East Carolina University Increase Understanding of Cancer Treatment Method; Software Predicts Efficacy of Photodynamic Therapy for Bladder Cancer
- Breast Cancer Treatment Touted ; Drug Useful Against Early-Stage Disease
- Research and Markets: Clinical Trials Have Shown the Lack of Activity of Estramustine in Hormone Refractory Prostate Cancer, But the Drug Is Still Commonly Used Because of the Lack of Alternatives
- Research and Markets: New Report Examines Hot Topics and Key Issues for Prostrate Cancer Treatment
 |
 |
User Comments (0)
RSS Feeds